Chief Scientific Officer Yoshitsugu Shitaka, Ph.D., won’t be so lucky. Astellas intends to create the new role of Chief ...

The drugmaker sees additional growth opportunities in ophthalmology and neuromuscular disorders, Chief Medical Officer ...

Astellas has, however, suffered some setbacks in its own gene therapy programmes, including most recently an FDA clinical hold on its phase 1/2 trial of AAV-based AT845 in adults with late-onset ...

Astellas has stayed busy inking cell therapy deals through Xyphos in recent months. Astellas pays Sangamo $20M upfront to improve neurological gene therapy capabilities Xyphos linked arms with ...

an Astellas company, to optimize next-generation induced pluripotent stem cell (iPSC)-derived cancer cell therapies. This collaboration underscores Ginkgo's capacity to deploy high-throughput ...

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Sangamo Biosciences (SGMO – Research Report) today and set a price target ...

Dyno has empowered therapeutic innovation through partnerships with leading gene therapy developers, including Astellas, Roche, and Sarepta, and with technology companies including NVIDIA.

"Teaming up with Universal Cells, part of Astellas, allows us to bring our ... you can leverage Ginkgo's capabilities in cell therapy and gene editing - from CAR-T to CRISPR and beyond - please ...